文献速递心律失常冠心病

基于房颤遗传风险的筛查效果:LOOP 随机试验二次分析

Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.
PubMed 文献 · J Am Coll Cardiol · 2025-10-29

该研究为 LOOP 随机试验预设的事后分析,纳入 5,656 例≥70 岁且有卒中危险因素、无房颤且具遗传数据的个体,按 1:3 随机接受植入式循环记录仪(ILR)筛查或常规护理。中位随访 5.4 年显示,ILR 筛查与较高遗传风险(PRS≥中位数)者卒中/系统性栓塞(SE)风险降低相关(HR 0.65),而较低遗传风险者无获益且大出血风险升高。

要点

  • PRS 较高的个体接受 ILR 筛查与卒中/SE 风险降低相关(HR 0.65)。
  • PRS 较低者接受 ILR 筛查未见卒中/SE 获益,且大出血风险升高(HR 1.71)。
  • PRS 每升高 1 个标准差与房颤发生率升高相关(HR 1.20)。

核心结论

  • ILR 筛查与较高房颤遗传风险个体卒中/SE 显著减少相关,而较低遗传风险个体无此获益。
  • 遗传易感性可能有助于筛选从房颤筛查中获益的个体,但结果属假设生成性。

研究设计与样本

  • LOOP 随机试验的预设事后分析,纳入 5,656 例≥70 岁、无房颤、有卒中危险因素且具遗传数据的个体。
  • 参与者按 1:3 随机接受 ILR 筛查或常规护理,遗传风险以房颤多基因风险评分(PRS_AF)评估。

主要发现

  • 中位随访 5.4 年,969 例(17.1%)诊断房颤,296 例(5.2%)发生卒中/SE,206 例(3.6%)发生大出血。
  • PRS_AF 每升高 1 个标准差与房颤发生率升高相关(HR 1.20;95% CI 1.13-1.28;P<0.001)。
  • ILR 筛查与 PRS_AF 对卒中/SE 存在显著交互作用(Pinteraction=0.006)。
  • PRS_AF≥中位数者中,ILR 筛查与卒中/SE 风险降低相关(HR 0.65;95% CI 0.43-0.97;P=0.036);PRS_AF<中位数者无显著关联(HR 1.06;95% CI 0.72-1.57;P=0.75)。
  • 较低 PRS_AF 水平者中,ILR 筛查与大出血风险升高相关(Pinteraction=0.036),PRS_AF<中位数者 HR 1.71(95% CI 1.12-2.64;P=0.011)。

关键数值与推荐

  • PRS_AF 每升高 1 个标准差,发生≥1 次持续≥24 小时房颤发作的 OR 为 1.35(95% CI 1.02-1.78;P=0.037)。

临床怎么用

  • 对房颤遗传风险较高(PRS_AF≥中位数)的老年高危个体,可考虑 ILR 筛查以降低卒中/SE 风险。
  • 对遗传风险较低者,ILR 筛查未见卒中/SE 获益且大出血风险升高,应谨慎选择。

局限性

  • 本研究为随机试验的事后分析,结果属假设生成性,需进一步验证。
  • 分析仅纳入具有遗传数据的参与者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polygenic risk scores (PRS) hold promise in risk stratification and screening for cardiovascular diseases, including atrial fibrillation (AF). OBJECTIVES: This study investigated the efficacy of AF screening for stroke prevention based on a PRS for AF. METHODS: This prespecified post hoc analysis of the randomized LOOP (Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-Risk Individuals) study included 5,656 AF-naive individuals aged ≥70 years with stroke risk factors and available genetic data. The participants were randomized 1:3 for screening with an implantable loop recorder (ILR) vs usual care. Genetic risk of AF was assessed using a PRS for AF (PRSAF). The primary outcome was a composite of stroke and systemic embolism (SE). Interaction between the randomization arm and PRSAF was assessed in cause-specific Cox regressions for the full cohort and across the observed range of polygenic risk using a continuous prediction grid. Secondary analyses included models stratified by PRS level, gene-screening interactions for major bleeding events, and associations between PRSAF and AF burden (≥1 episode lasting ≥24 hours among participants with ILR-detected AF). RESULTS: Over a median follow-up period of 5.4 years, 969 participants (17.1%) received a diagnosis of AF, 296 (5.2%) had stroke/SE, and 206 (3.6%) had major bleeding. PRSAF was associated with higher rates of AF (HR per SD increase: 1.20; 95% CI: 1.13-1.28; P < 0.001). A significant interaction was observed between ILR screening and PRSAF for stroke/SE (Pinteraction = 0.006). ILR screening was associated with lower rates of stroke/SE in individuals with PRSAF ≥median (HR: 0.65; 95% CI: 0.43-0.97; P = 0.036) but not in those with PRSAF <median (HR: 1.06; 95% CI: 0.72-1.57; P = 0.75). ILR screening was associated with higher rates of major bleeding at lower levels of PRSAF (Pinteraction = 0.036), corresponding to a HR of 1.71 (95% CI: 1.12-2.64; P = 0.011) in those with PRSAF <median. A 1-SD increase in PRSAF was associated with an OR of 1.35 (95% CI: 1.02-1.78; P = 0.037) for having ≥1 AF episode lasting ≥24 hours. CONCLUSIONS: ILR screening for AF was associated with a significant reduction in stroke/SE in individuals with higher genetic risk of AF but not in those with lower genetic risk. These hypothesis-generating findings indicate that genetic predisposition may aid in selecting individuals who benefit from AF screening.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Vad, Diederichsen, Xing, et al. Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. J Am Coll Cardiol. 2025. PMID: 41159983. doi:10.1016/j.jacc.2025.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。